Ocera Therapeutics Inc. (NASDAQ:OCRX) shares saw strong trading volume on Wednesday . 287,917 shares changed hands during trading, an increase of 308% from the previous session’s volume of 70,507 shares.The stock last traded at $2.49 and had previously closed at $2.48.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Tuesday. Brean Capital reaffirmed a “buy” rating on shares of Ocera Therapeutics in a research report on Tuesday, April 12th.

The firm has a 50-day moving average price of $2.46 and a 200-day moving average price of $2.73. The stock’s market capitalization is $53.05 million.

Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.02. On average, analysts expect that Ocera Therapeutics Inc. will post ($1.36) earnings per share for the current year.

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.